Enhancer Reprogramming in PRC2-deficient Malignant Peripheral Nerve Sheath Tumors Induces a Targetable De-Differentiated State
The University of Texas MD Anderson Cancer Center, Broad Institute of MIT and Harvard,Landers Sharon M.,Schulz Jonathan,Terranova Christopher, Louisiana State University School of Medicine,Bhalla Angela D.,Beird Hannah C.,Wu Chia-Chin,Jiang Yingda,Mao Xizeng,Lazcano Rossana,Gite Swati,Ingram Davis R.,Yi Min,Zhang Jianhua,Keung Emily Z.,Scally Christopher P.,Roland Christina L.,Hunt Kelly K.,Feig Barry W.,Futreal P. Andrew,H. Lee Moffitt Cancer Center and Research Institute,Wang Wei-Lien,Lazar Alexander J.,Slopis John M.,Wilson-Robles Heather,Wiener Dominique J.,McCutcheon Ian E.,Colorado State University,Baylor College of Medicine Acta Neuropathologica（2021）
Key words
Malignant peripheral nerve sheath tumor,Polycomb repressor complex 2,Neural-crest phenotype,Epigenomic reprogramming,BRD4 inhibitor,Enhancer activation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper